• Overview
  • Eligibility
  • More info
  • Locations

A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT00004012)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.
  • Drug: capecitabine
    Ages eligible for Study
    all
    Genders eligible for Study
    Female
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Determine the response rate and time to treatment failure in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with oral capecitabine. II. Determine the tolerability and safety of this regimen in these patients.

    OUTLINE: Patients receive oral capecitabine twice daily for 14 days. Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity.

    PROJECTED ACCRUAL: A total of 14-35 patients will be accrued for this study.

    1 locations

    United States (1)
    • Memorial Sloan-Kettering Cancer Center
      New York, New York, United States, 10021
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 November, 1998
    Updated:
    19 June, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!